Pluristem Therapeutics, Inc. (PSTI) financial statements (2023 and earlier)

Company profile

Business Address MATAM ADVANCED TECHNOLOGY PARK
HAIFA, 3508409
State of Incorp. NV
Fiscal Year End June 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q2
9/30/2021
Q1
6/30/2021
Q4
3/31/2021
Q3
12/31/2020
Q2
9/30/2020
Q1
6/30/2020
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:68,84879,15488,21973,89346,24453,12758,992
Cash and cash equivalents18,71514,61131,24112,2657,8246,6258,270
Short-term investments39,46846,06033,70935,10535,22833,81337,514
Other undisclosed cash, cash equivalents, and short-term investments10,66518,48323,26926,5233,19212,68913,208
Restricted cash and investments20760759758640555555
Receivables      26
Other current assets  1,8241,8642,1581,6982,122
Other undisclosed current assets(8,902)(16,935)(23,269)(26,523)(3,192)(12,689)(13,234)
Total current assets:60,15362,82667,37149,82045,25042,69148,461
Noncurrent Assets
Operating lease, right-of-use asset8,4415737289041,0531,1901,259
Property, plant and equipment8901,1761,4991,8092,0892,2602,516
Long-term investments and receivables10,96518,48323,26925,9373,15212,13412,653
Long-term investments10,96518,48323,26925,9373,15212,13412,653
Other noncurrent assets18679132912
Other undisclosed noncurrent assets717683664695706646631
Total noncurrent assets:21,03120,92126,16729,3547,01316,25917,071
TOTAL ASSETS:81,18483,74793,53879,17452,26358,95065,532
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,3197,5618,4676,8976,5955,3185,475
Accounts payable2,6062,3032,5262,1102,8541,7951,968
Accrued liabilities3,7135,2585,9414,7873,7413,5233,018
Employee-related liabilities      489
Deferred revenue      126
Other undisclosed current liabilities3,2762,8043,0503,0193,4013,0272,386
Total current liabilities:9,59510,36511,5179,9169,9968,3457,987
Noncurrent Liabilities
Long-term debt and lease obligation30,76923,53823,950169159385565
Long-term debt, excluding current maturities23,15823,44423,850    
Operating lease, liability7,61194100169159385565
Liabilities, other than long-term debt9809379209539601,272879
Liability, pension and other postretirement and postemployment benefits980937920953960892879
Other liabilities     380 
Total noncurrent liabilities:31,74924,47524,8701,1221,1191,6571,444
Total liabilities:41,34434,84036,38711,03811,11510,0029,431
Stockholders' equity
Stockholders' equity attributable to parent, including:39,84048,90757,15168,13641,14848,94856,101
Additional paid in capital392,233390,360387,172383,589342,347337,593336,257
Accumulated deficit(352,393)(341,453)(330,021)(315,453)(301,199)(288,645)(280,156)
Stockholders' equity note, subscriptions receivable(39,840)(48,907)(57,151)(68,136)(41,148)(48,948)(56,101)
Other undisclosed stockholders' equity attributable to parent39,84048,90757,15168,13641,14848,94856,101
Total stockholders' equity:39,84048,90757,15168,13641,14848,94856,101
TOTAL LIABILITIES AND EQUITY:81,18483,74793,53879,17452,26358,95065,532

Income statement (P&L) ($ in thousands)

12/31/2021
Q2
9/30/2021
Q1
6/30/2021
Q4
3/31/2021
Q3
12/31/2020
Q2
9/30/2020
Q1
6/30/2020
Q4
Revenues  55    
Other undisclosed gross profit      1
Gross profit:      1
Operating expenses(10,829)(11,479)(14,609)(14,383)(13,096)(9,002)(8,633)
Other undisclosed operating income34382215822265118
Operating loss:(10,795)(11,441)(14,587)(14,225)(13,074)(8,737)(8,514)
Nonoperating income      378
Other undisclosed income from continuing operations before equity method investments, income taxes  332    
Loss before gain (loss) on sale of properties:(10,795)(11,441)(14,255)(14,225)(13,074)(8,737)(8,136)
Other undisclosed net income 22,873100,156    
Net income (loss):(10,795)11,43285,901(14,225)(13,074)(8,737)(8,136)
Other undisclosed net income (loss) attributable to parent(145)(22,864)(100,469)(29)520248 
Net loss attributable to parent:(10,940)(11,432)(14,568)(14,254)(12,554)(8,489)(8,136)
Other undisclosed net income available to common stockholders, basic  99,730    
Net income (loss) available to common stockholders, diluted:(10,940)(11,432)85,162(14,254)(12,554)(8,489)(8,136)

Comprehensive Income ($ in thousands)

12/31/2021
Q2
9/30/2021
Q1
6/30/2021
Q4
3/31/2021
Q3
12/31/2020
Q2
9/30/2020
Q1
6/30/2020
Q4
Net income (loss):(10,795)11,43285,901(14,225)(13,074)(8,737)(8,136)
Comprehensive income (loss), net of tax, attributable to parent:(10,795)11,43285,901(14,225)(13,074)(8,737)(8,136)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: